Can You Build Muscle on Ozempic? What the Research Actually Says

What the Clinical Trials Actually Show

This question gets muddled because two different things are being discussed as if they are the same. The first is whether GLP-1 medications prevent muscle building. The second is whether most GLP-1 users are losing muscle. Both things can be true simultaneously — and they are.

The clinical trial data is clear on lean mass losses. In the STEP 1 trial — the pivotal semaglutide trial published in the New England Journal of Medicine in 2021 — approximately 25–40% of total weight lost came from lean tissue. A post-hoc analysis of the SURMOUNT-1 tirzepatide trial found pooled lean mass loss of around 10.9% of lean body mass over 72 weeks. A Lancet Diabetes & Endocrinology 2025 post-hoc analysis of the SURPASS-3 MRI trial examined tirzepatide’s effects on muscle composition specifically, confirming meaningful but not disproportionate lean mass changes.

Those numbers sound alarming until you understand two things.

First, the proportion of lean mass lost during GLP-1 therapy (25–40%) is broadly similar to what is seen during other forms of significant calorie restriction, including dietary interventions and bariatric surgery. It is not a unique drug effect — it is the normal physiological response to being in a large calorie deficit.

Second, almost none of the major clinical trials included structured resistance training or protein targets. The participants lost lean mass the way anyone loses lean mass when they significantly reduce calorie intake without doing anything to protect muscle. That is the gap the research does not close by itself.

What Ozempic Does — and Does Not Do — to Muscle

Understanding this distinction is the foundation of everything else in this article.

What GLP-1 medications do not do: They do not directly inhibit muscle protein synthesis. They do not block the anabolic response to resistance training. They do not prevent the uptake of amino acids by muscle tissue. There is no pharmacological mechanism by which semaglutide or tirzepatide directly causes muscle breakdown. This point is well established in the literature — a 2024 review in Circulation described lean mass changes during GLP-1 therapy as an “adaptive rather than maladaptive response” to weight reduction.

What GLP-1 medications do: They reduce appetite dramatically. For most users, food intake drops 30–50%. That calorie deficit is the primary driver of weight loss — but it also means the body has less energy available overall. Without a deliberate signal to preserve muscle (resistance training) and adequate building materials (protein), the body will use lean tissue as an energy source alongside fat. This is not what the medication does. This is what calorie restriction does when unmanaged.

There is also an emerging and genuinely interesting area of research suggesting GLP-1 receptors may have direct effects on skeletal muscle. A 2025 systematic review in the Journal of Cachexia, Sarcopenia and Muscle examined GLP-1 receptor agonist effects on mitochondrial function within skeletal muscle and found improvements in mitochondrial energy efficiency. A 2023 study found that liraglutide and semaglutide may improve obesity-induced muscle atrophy through the SIRT1 pathway. This research is early and not yet translatable to clear clinical recommendations — but it points toward a potential future where GLP-1 medications are understood as having muscle-relevant effects beyond simply reducing appetite.

The Evidence for Building Muscle While on GLP-1

The most compelling evidence comes from a 2025 case series published in SAGE Open Medicine, conducted by researchers at Texas Tech University. It is the most direct available evidence that body recomposition — simultaneously losing fat and gaining muscle — is achievable during active GLP-1 therapy.

Three patients at a virtual health clinic who had DXA body composition scans before and during treatment with semaglutide or tirzepatide were analysed. All three prioritised resistance training (3–5 sessions per week) and maintained protein intake of 1.6–2.3g per kilogram of fat-free mass per day throughout treatment.

The results were striking:

• Case 1: Lost 33% of total body weight. Fat mass fell 53.4%. Lean soft tissue fell 6.9% — dramatically below the clinical trial average of 25–40% lean contribution to total weight loss.
• Case 2: Lost 26.8% of total body weight. Fat mass fell 61.6%. Lean soft tissue increased by 2.5%. Full body recomposition while losing more than a quarter of body weight.
• Case 3: Lost 13.2% of total body weight. Fat mass fell 46.9%. Lean soft tissue increased by 5.8%. The clearest example of simultaneous fat loss and muscle gain during GLP-1 therapy in the published literature.

These were not athletes. These were people with BMIs between 32.9 and 51.9 — the same population range as typical GLP-1 users. The difference between their outcomes and the clinical trial averages was entirely accounted for by resistance training and protein intake.

Supporting evidence comes from a 2025 Medscape-reported study of 200 adults on semaglutide or tirzepatide. All participants received guidance on resistance training and protein intake from the first day of treatment. At six months they had lost approximately 13% of total body weight but only 3% of muscle mass. In unguided trials the same weight loss typically carries 10–20 times more lean tissue loss in absolute terms.

Why Most GLP-1 Users Are Not Building Muscle

The evidence that muscle building is possible is clear. So why are most GLP-1 users losing lean mass rather than gaining it? Three specific reasons account for almost all of it.

1. Nobody told them to resistance train

The clinical trials that produced the 25–40% lean mass loss figures did not include structured resistance training protocols. Neither do most GLP-1 prescribing workflows. A 2025 paper in PMC reviewing strategies for minimising muscle loss during GLP-1 therapy noted that clinical adoption of these medications has “outpaced the updating of clinical practice guidelines”, leaving patients without guidance on muscle preservation. Most GLP-1 users are navigating this entirely on their own, without knowing that resistance training is not optional — it is the primary tool for keeping lean mass during the weight loss process.

2. Appetite suppression tanks protein intake

To build or preserve muscle, you need to consume adequate protein relative to your body weight every day. GLP-1 medications reduce appetite so effectively that many users struggle to eat enough of anything, let alone prioritise protein within a dramatically reduced intake. When food choices become difficult due to nausea or appetite suppression, people tend to gravitate toward easy, carbohydrate-heavy options rather than protein-dense foods. The result is that daily protein intake falls far short of what muscle preservation requires — and the body compensates by breaking down lean tissue for amino acids.

3. The wrong type of exercise

When GLP-1 users do exercise, they most commonly choose cardio — walking, cycling, or low-intensity aerobic activity. These are excellent for cardiovascular health and calorie expenditure. They are not effective for preserving or building muscle mass. Muscle growth requires mechanical tension — the progressive loading of muscle tissue against resistance that signals the body to synthesise new muscle protein. Cardio does not provide this signal. Only resistance training does.

The Complete Protocol for Building Muscle on GLP-1

Both components below are required. Neither works without the other. Resistance training without adequate protein provides the stimulus but not the building materials. Protein without resistance training provides the building materials but no reason to build.

Training: what the evidence supports

Frequency: Train each major muscle group 2–3 times per week. A review of minimal-dose resistance training published in Sports Medicine (2022) established that this frequency is sufficient to trigger hypertrophy even at moderate intensities. Three full-body sessions per week is the most practical structure for most GLP-1 users who are new or returning to training.

Exercise selection: Prioritise compound movements that recruit multiple muscle groups simultaneously. These provide the greatest anabolic stimulus per unit of effort:

• Lower body: Squats, leg press, Romanian deadlifts, lunges
• Upper body pull: Dumbbell rows, cable rows, lat pulldowns
• Upper body push: Dumbbell or barbell chest press, overhead press, push-ups
• Posterior chain: Deadlifts, hip thrusts, glute bridges

Sets and reps: Start with 2–3 sets of 8–12 repetitions per exercise. Use a weight that is genuinely challenging in the final 2–3 reps. The last few reps of each set must feel difficult — this is the stimulus that triggers muscle protein synthesis.

Progressive overload: This is the most important and most neglected principle. Each week or every two weeks, add weight, reps, or sets. Without progressive challenge, the muscle has no reason to grow. The 2025 case series patients who gained lean soft tissue while losing over a quarter of their body weight maintained structured progressive resistance training throughout — this was not coincidental.

Timing relative to GLP-1 injection: Most users find energy and gastrointestinal comfort varies across the week after injection. Schedule harder training sessions for the days when you feel best — typically 3–5 days after injection for weekly dose users. This is practical management of side effects, not a pharmacological requirement.

Nutrition: the protein strategy

Daily target: Aim for 1.2–2.0 grams of protein per kilogram of body weight per day. The higher end of this range (1.6–2.0g/kg) is appropriate for people actively resistance training, people over 50, and people who have already experienced significant lean mass loss. The SAGE Open Medicine case series patients who gained lean soft tissue were hitting 1.6–2.3g per kilogram of fat-free mass — a meaningfully higher target than general population recommendations.

Protein distribution: Research on protein timing consistently shows that consuming at least 20–30g of protein per eating occasion is needed to meaningfully trigger muscle protein synthesis. Spreading intake across 3–5 occasions per day is more effective than consuming the same total amount in one or two meals. On GLP-1 medications where appetite suppression limits meal size, this typically means using protein-rich snacks strategically between meals.

The protein-first principle: When appetite is suppressed and you can only manage a small meal, eat protein first. Before anything else on the plate. This ensures your most critical macronutrient is consumed even on low-appetite days, rather than being displaced by more palatable but lower-protein options.

Post-training nutrition: Consuming 25–40g of protein within 1–2 hours after resistance training takes advantage of the post-exercise window during which muscle protein synthesis is elevated. This does not require a large meal — a protein shake, Greek yoghurt with protein powder, or cottage cheese is sufficient.

Creatine monohydrate: The most evidence-backed supplement for muscle building. A 2025 PubMed review of nutrition support during GLP-1 therapy listed creatine alongside branched-chain amino acids as potentially valuable supplements for muscle preservation. Creatine increases the energy available to muscle cells during high-intensity exercise, allows greater training volume, and improves recovery. 3–5g per day is the standard dose. No loading phase is required. It is safe, inexpensive, and one of the most extensively studied supplements in exercise science.

Does It Matter Which GLP-1 You Are On?

The fundamental biology is the same across all GLP-1 medications — Ozempic, Wegovy, Mounjaro, and Zepbound all work through appetite suppression and do not directly inhibit muscle protein synthesis. However, there are meaningful differences worth knowing.

Semaglutide (Ozempic/Wegovy) vs Tirzepatide (Mounjaro/Zepbound): The Lancet Diabetes & Endocrinology 2025 SURPASS-3 MRI post-hoc analysis examined tirzepatide’s effects on muscle composition specifically. The authors noted that no direct comparisons between selective GLP-1 receptor agonists and tirzepatide on muscle composition had been reported, making it impossible to determine whether the dual GIP/GLP-1 mechanism of tirzepatide produces different muscle outcomes. There is some preclinical evidence suggesting GIP receptor stimulation may have positive effects on skeletal muscle glucose uptake, but this has not been confirmed in clinical outcomes data.

Higher doses produce larger calorie deficits: Higher doses of any GLP-1 medication produce greater appetite suppression and therefore larger calorie deficits. This means hitting protein targets becomes harder as dose increases. Users titrating to higher doses should proactively adjust their protein strategy as appetite suppression deepens.

Side effect profile affects training: Nausea is most common early in treatment and during dose escalation. Training intensity may need to be reduced during these periods. This is temporary — as tolerance develops, training can return to full intensity. The priority during high-nausea periods is maintaining training frequency and protein intake at whatever level is achievable, even if intensity is reduced.

How to Know It Is Working

Building muscle during GLP-1 treatment can feel confusing to track because the scale may not move consistently — or may even plateau — as muscle growth offsets ongoing fat loss. Do not use the scale as your only measure. Use these markers instead:

• Strength is increasing week over week. If you are adding weight to the bar, adding reps, or finding previously challenging sets easier — muscle protein synthesis is active. Strength gain is the most reliable early indicator.
• Energy between meals is improving. As lean mass increases and blood sugar stability improves, the energy crashes common early in GLP-1 treatment reduce. Better between-meal energy is a reliable metabolic marker.
• Visible muscle tone in trained areas. By weeks 6–10 of consistent resistance training, most people notice visible definition in the muscle groups they are targeting — typically shoulders, arms, and legs first.
• Clothes fitting differently. Body composition changes before scale weight does. Waistbands loosening while sleeves fill out slightly is the classic sign of simultaneous fat loss and muscle gain.
• Reduced soreness over time. As muscle adapts to resistance training, recovery between sessions shortens. Persistent extreme soreness that does not reduce over weeks signals under-recovery — usually from insufficient protein or sleep.
• Scale weight stalling while body composition improves. This is not a plateau — it is recomposition working. If fat is being lost and muscle is being gained simultaneously, total weight may remain similar for weeks while your body composition changes meaningfully.

Research & References